Kineta

About:

Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.

Twitter/X: kinetabio

Top Investors: SFC Capital, Wellcome Trust, National Institute of Allergy and Infectious Diseases, Keiretsu Capital, AngelMD

Description:

Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold.

Total Funding Amount:

$98M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)kinetabio.com

Founders:

Charles Magness, Shawn Iadonato

Number of Employees:

11-50

Last Funding Date:

2023-10-04

IPO Status:

Public

Industries: